Skip to main content

Table 5 Multiple Tobit regression adjusting for age (right ear)

From: Baseline audiological profiling of South African females with cervical cancer: an important attribute for assessing cisplatin-associated ototoxicity

Frequency (Hz) No. of non-responses Risk factors
Estimate of coefficient (SE); p-value
HIV seropositive NCD
LFPTT
125 0 0.79 (2.78); 0.77 2.42 (2.13); 0.26
250 0 1.72 (3.26); 0.59 − 0.01 (2.50); 0.99
500 0 4.17 (4.02); 0.3 0.26 (2.56); 0.92
MFPTT
1000 1 3.52 (2.68); 0.19 − 2.52 (3.08); 0.41
2000 0 1.81 (4.52); 0.69 − 0.17 (3.46); 0.96
HFPTT
4000 0 1.93 (3.2); 0.67 1.70 (3.42); 0.62
8000 0 1.07 (5.15); 0.83 3.93 (3.94); 0.32
9000 0 4.18 (5.32); 0.43 5.06 (4.07); 0.21
EHFPTT
10,000 1 5.51 (5.84); 0.34 3.32 (4.47); 0.46
11,200 1 4.40 (6.21); 0.01 3.88 (4.76); 0.41
12,500 12 (14.6%) 8.32 (6.02); 0.16 − 5.96 (4.54); 0.38
14,000 31 (37.8%) 6.42 (6.79); 0.34 − 0.49 (5.33); 0.93
16,000 57 (70%) 0.99 (7.71); 0.89 0.76 (6.0); 0.89
18,000 75 (91%) 0.03 (3.45); 0.99 3.53 (2.99); 0.24
20,000 79 (96%) 9.58 (4.08); 0.02 − 0.26 (0.48); 0.59
  1. LFPTT, Low-frequency pure tone thresholds; MFPTT, Mid-frequency pure tone thresholds; HFPTT, High frequency pure tone thresholds; EHFPTT, Extended high-frequency pure tone thresholds; NCD, Hypertension and Diabetes